Innoviva, Inc. INVA

Latest FY: 2025 Healthcare Biotechnology
Market Price $21.20
Market Cap $1.53B
P/E Ratio 6.42
Quick Peer Compare (Healthcare):
Revenue (FY 2025) ↑14.7% YoY
$411.33M
3-Yr CAGR: 7.5%
Net Income ↑1,059.2% YoY
$271.17M
Net Margin: 65.9%
Free Cash Flow ↑3.9% YoY
$195.80M
FCF Yield: 12.78%
EPS (Diluted) ↑816.7% YoY
$3.30
Basic: $4.02
Return on Equity Efficiency
23.1%
ROA: 1,014.8%

📊 Multi-Year Historical Performance & Trends

Financial Performance History Revenue, Net Income & Free Cash Flow
Margins Trend (%) Gross, Operating & Net Margins
Balance Sheet Strength Cash, Debt & Equity
Cash Flow Generation Operating Cash Flow vs CapEx vs FCF

📈 Year-over-Year (YoY) Growth History (INVA)

All monetary values in millions ($M)
Fiscal Year Revenue Revenue YoY Gross Profit Net Income Net Inc YoY Diluted EPS EPS YoY Op. Cash Flow Free Cash Flow FCF YoY
FY 2016 $133.6M $81.2M $59.5M $0.53 $61.0M $60.7M
FY 2017 $217.2M +62.6% $173.6M $134.1M +125.3% $1.17 +120.8% $141.7M $141.7M +133.5%
FY 2018 $261.0M +20.2% $237.1M $395.1M +194.5% $3.53 +201.7% $223.5M $223.5M +57.7%
FY 2019 $261.0M +0.0% $242.4M $157.3M -60.2% $1.43 -59.5% $257.5M $257.4M +15.2%
FY 2020 $336.8M +29.0% $318.5M $224.4M +42.7% $2.02 +41.3% $313.1M $313.1M +21.6%
FY 2021 $391.9M +16.4% $372.8M $265.9M +18.5% $2.87 +42.1% $363.8M $363.8M +16.2%
FY 2022 $331.3M -15.4% $315.6M $213.9M -19.5% $2.37 -17.4% $201.7M $201.7M -44.6%
FY 2023 $310.5M -6.3% $291.3M $179.7M -16.0% $2.20 -7.2% $141.1M $140.7M -30.3%
FY 2024 $358.7M +15.5% $336.5M $23.4M -87.0% $0.36 -83.6% $188.7M $188.4M +34.0%
FY 2025 $411.3M +14.7% $394.6M $271.2M +1,059.2% $3.30 +816.7% $196.9M $195.8M +3.9%
$

Valuation

Market Price $21.20
Market Cap $1.53B
Enterprise Value $1.24B
P/E Ratio 6.42
P/B Ratio 1.33
FCF Yield 12.78%
Dividend Yield 18.97%
Shares Outstanding 73,808,700
%

Profitability & Margins

Gross Margin 95.94%
Operating Margin 39.81%
Net Margin 65.92%
Return on Equity (ROE) 23.12%
Return on Assets (ROA) 1,014.80%
Asset Turnover 15.39x
Revenue 3-Yr CAGR 7.47%
🛡️

Financial Health & Liquidity

Current Ratio 0.54
Cash Ratio 11.09
Debt / Equity 0.220
Debt / Assets 9.645
Cash & Equivalents $550.94M
Total Debt $257.73M
Book Value / Share $15.89
💧

Cash Flow Efficiency

Operating Cash Flow $196.93M
Capital Expenditures (CapEx) $1.13M
Free Cash Flow $195.80M
OCF / Revenue 47.88%
FCF / Revenue 47.60%
FCF 3-Yr CAGR -0.98%
🏷️

Per Share Metrics

EPS (Diluted) $3.30
EPS (Basic) $4.02
Dividends / Share $4.02
Book Value / Share $15.89
EPS YoY Growth 816.67%
🏛️

Balance Sheet (FY 2025)

Total Assets $26.72M
Total Liabilities $49.70M
Stockholders' Equity $1.17B
Current Assets $26.72M
Current Liabilities $49.70M